AMEDICA Announces Participation in Australian Spine Conference
February 27 2018 - 9:00AM
Amedica Corporation (NASDAQ: AMDA), an innovative biomaterial
company that develops and commercializes silicon nitride for
biomedical applications, is pleased to announce that it has been
invited to present at the 29th Annual Scientific Meeting of the
Australian Spine Society. The forum, attended by spine
surgeons throughout Australia, is a new opportunity in light of
Australian regulatory approval in 2017 for Amedica products.
Amedica’s presentation is titled “Effect of Surface Topography on
the Bacteriostatic and Osseointegration Behavior of Silicon
Nitride” and summarizes an independent investigation supporting the
unique antibacterial properties of silicon nitride.
“Australia is of particular interest since the
first spinal fusion with silicon nitride was performed by
Australian surgeons 30 years ago. The meeting is a great
platform to introduce Amedica’s silicon nitride to Australian
surgeons, and to build new sales in that market. This is an
exciting opportunity to leverage scientific data and knowledge
toward identifying new markets and sales opportunities for our
products. ” said Dr. Sonny Bal, MD, MBA, JD, PhD; Chairman and
CEO of Amedica.
About Amedica
Corporation
Amedica is focused on the development and
application of spinal interbody implants made with medical-grade
silicon nitride ceramic. Amedica markets spinal fusion products and
is developing implants for other biomedical applications, such as
wear- and corrosion-resistant hip and knee bearings, and dental
implants. The Company’s products are manufactured in its FDA
registered and ISO 13485 certified manufacturing facility, and it
has a partnership with Kyocera, one of the world’s largest ceramic
manufacturers. Amedica’s FDA-cleared and CE-marked spine products
are currently marketed in the U.S. and select markets in Europe and
South America through its distributor network, as well as OEM and
private label partnerships.
For more information on Amedica
or its silicon nitride material platform, please visit
www.amedica.com.
Forward-Looking Statements
This press release contains statements that
constitute forward-looking statements within the meaning of the
Securities Act of 1933 and the Securities Exchange Act of 1934, as
amended by the Private Securities Litigation Reform Act of 1995.
Such statements include statements regarding the building of new
sales in the Australian market. A discussion of those risks and
uncertainties can be found in Amedica’s Risk Factors disclosure in
its Annual Report on Form 10-K/A, filed with the Securities and
Exchange Commission (SEC) on December 27, 2017, and in Amedica’s
other filings with the SEC. Amedica disclaims any obligation to
update any forward-looking statements.
Contacts:
Amedica IR
801-839-3502
IR@amedica.com
AMEDICA CORP (NASDAQ:AMDA)
Historical Stock Chart
From Sep 2024 to Oct 2024
AMEDICA CORP (NASDAQ:AMDA)
Historical Stock Chart
From Oct 2023 to Oct 2024